title: Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma.
abstract: Eighty-two dogs with lymphoma received a single 15-week course of chemotherapy, after which treatment was ceased until relapse. Fifty-six dogs (68%) achieved complete remission for a median 1st remission duration of 20 weeks. Forty-eight dogs relapsed, of which 30 repeated the induction cycle. In 22 of these dogs, 1st remission had been short, and they received maintenance chemotherapy; the other 8 dogs received 2 or 3 cycles of induction chemotherapy. Second remission rate for these 30 dogs was 87% (26 dogs). Overall disease control for the 38 dogs that remained on protocol was 44 weeks, which was not markedly shorter than for dogs treated with a previously reported protocol in which maintenance chemotherapy was instituted in all dogs after an identical 1st induction (VELCAP-L). Dogs that were febrile and dogs that were dyspneic were less likely to achieve a complete remission to induction chemotherapy. Of dogs that achieved a complete remission, those that were thrombocytopenic at entry had a shorter 1st remission, and dogs that were anorexic at entry had shorter overall disease control. There was a correlation between 1st remission duration and length of any subsequent remission obtained. The incidence of toxicity was high, particularly after the combination of doxorubicin and vincristine. Dose reductions because of toxicity did not markedly reduce remission duration. We conclude that discontinuous chemotherapy may reduce patient visits in a small number of patients because of long-term disease control. Delaying maintenance chemotherapy until after 2nd remission is achieved does not markedly affect overall disease control.
authors.affiliation: Harrington Oncology Program, Tufts University School of Veterinary Medicine, North Grafton, MA 01536, USA. antony.moore@tufts.edu
authors.forename: A S
authors.initials: AS
authors.lastname: Moore
authors.forename: S M
authors.initials: SM
authors.lastname: Cotter
authors.forename: W M
authors.initials: WM
authors.lastname: Rand
authors.forename: C A
authors.initials: CA
authors.lastname: Wood
authors.forename: L E
authors.initials: LE
authors.lastname: Williams
authors.forename: C A
authors.initials: CA
authors.lastname: London
authors.forename: A E
authors.initials: AE
authors.lastname: Frimberger
authors.forename: D A
authors.initials: DA
authors.lastname: L'Heureux
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage; D001947:Breeding; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D008223:Lymphoma / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D011996:Records / Q000662:veterinary; D012189:Retrospective Studies; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D001215:Asparaginase; D011241:Prednisone